Home > Boards > US Listed > Medical - Healthcare >

Biocept, Inc. (BIOC)

Add BIOC Price Alert      Hide Sticky   Hide Intro
Moderator: bigarow, Golden_Cross
Search This Board: 
Last Post: 3/24/2018 11:10:16 AM - Followers: 73 - Board type: Free - Posts Today: 1

Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA or ctDNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and OncoCEE-LUTM for non-small cell lung cancer and OncoCEE- GATM for Gastric Cancer and plans to introduce additional CLIA validated tests for breast, lung, colorectal, melanoma, prostate and other solid tumors based on its proprietary technology platforms over the coming months.


The Leader in Clinical Trial Management Solutions

BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading Medical Imaging services, Cardiac Safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 - through a network of offices in the U.S., Europe, and Asia.


IRT Sourcing Models, Breaking with Convention (Part 2)

Submitted by Steve Goldstein on February 18, 2015 - 4:34pm

What Makes an IRT Great for Technology Transfer?

In the last blog we talked about how technology transfer is gaining ground on the conventional Software as a Service (SaaS) IRT sourcing model. In this blog post, I will explain the advantages of the technology and design behind Trident that make it particularly well-suited for IRT technology transfer. So let's dive right in.

IRT Sourcing Models, Breaking with Convention (Part 1)

Submitted by Steve Goldstein on February 18, 2015 - 4:02pm

Technology Transfer Gaining on Saas

When it comes to Interactive Response Technology (IRT) – systems used to perform subject randomization, drug dispensing and study drug resupply – Software as a Service (SaaS) continues to be the conventional delivery model including here at BioClinica.

Key Insights from SCDM Euro Leadership Forum

Submitted by Jonathan Andrus on February 6, 2015 - 4:15pm

Break-out Group Dissects the Development of a Risk-Based Approach To Clinical Trial Management

As SCDM's 2014 Chair I had the honor of presenting the keynote at the EU Leadership Forum held in The Netherlands, December 2014. Celebrating the organization's 20th Anniversary and all that's been accomplished, we took a light-hearted look at the Evolution of the Clinical Data Management Role.

Escalating Role of Medical Imaging in AD Clinical Trials

Submitted by Eli Berdougo on January 30, 2015 - 1:12pm

Studies Reveal Impact of Implementing, Standardizing, and Developing Neuroimaging Endpoints in Alzheimer's Disease Trials

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. Disease modifying therapies are desperately needed and many potential treatments are currently being tested in clinical trials. The role and impact of medical imaging in AD trials continues to grow, especially as clinicians and scientists seek to define and treat AD at the earliest stages of disease.

Risk-Based Monitoring Technology: 5 Essential Capabilities

Submitted by Courtney McBean on January 27, 2015 - 2:05pm

If you've spent time researching risk-based monitoring (RBM) over the past year, you know dozens of academics, CROs, clinical trial practitioners, and statisticians have proposed varied approaches based on sponsor needs and trial designs. Unfortunately, despite an abundance of theoretical perspectives on RBM, clinical trial teams soon discover a significant gap still exists between perspectives and actual tools to enable real-world RBM implementation.

Time to Take Action and Make Risk-Based Monitoring a Reality

Submitted by Courtney McBean on January 19, 2015 - 12:23pm

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

What’s New with CDISC Standards?

Submitted by Jennifer Price on December 16, 2014 - 11:13am

Progress on CDISC Standards has come at a quickened pace in recent years. Helping make advancement of industry-wide standards possible is collaboration among CDISC and other participating organizations (Critical Path Institute, Association of Clinical Research Organizations, Innovative Medicines Initiative, and National Cancer Institute). Joining in the collaboration are regulatory authorities and the pharma industry itself, as well as TransCelerate Biopharma which continues to press forward with its standards initiative.

Evolution of the Clinical Data Management Role, 1994-2014

Submitted by Jonathan Andrus on December 9, 2014 - 12:11pm

20-Year Retrospective

The role of the Clinical Data Manager (CDM) has changed immensely since 1994, both in terms of role and function. Let's take a fun retrospective look at the great strides made in our field over these last 20 years, and more importantly, where the CDM role is headed. Let's begin with 1994, in honor of the Society of Clinical Data Management (SCDM), which commemorated its 20th Anniversary in 2014.

3 Reasons to Share Data from Unsuccessful Clinical Trials

Submitted by Eli Berdougo on November 25, 2014 - 4:53pm
3 Reasons to Share Data from Unsuccessful Clinical Trials

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.

eSource: Are You On-Trend with Other Sponsors?

Submitted by Jennifer Price on November 12, 2014 - 11:17am

eSource is a topic that has everyone talking and it continues to dominate the conversation at industry gatherings, including the annual SCDM conference held earlier this fall. From what I heard there − and continue to hear – sponsors' experience with eSource runs the full gamut.

Why 'Intelligent Monitoring' Is Even Smarter than Risk-Based Monitoring

Submitted by Courtney McBean on October 31, 2014 - 1:27pm

When I speak on the topic of risk-based monitoring (RBM) at industry events, someone invariably comes up afterward to say how nice it is we finally stopped talking about risk-based monitoring!

eSource: Still in the Shallow End of the Pool?

Submitted by Jennifer Price on October 23, 2014 - 3:25pm

Dipping a toe in the water is always easier than jumping right into something new.

I am reminded of this old axiom as I look back at the recent SCDM conference and see it holds true for eSource.

Testing different eSource modalities within a controlled environment is one way to get acclimated and explore the use of eSource in your clinical trials while building experience – all in a low-risk way. Beginning with data that's directly entered as eSource is a whole lot easier and safer than attempting to hit it 100 percent from the high dive on the first try.

7 Principles of eSource Use

Submitted by Jennifer Price on October 17, 2014 - 10:31am
7 Principles of eSource Use

As I write this, I’m on a return flight home to Philadelphia from Las Vegas where I attended the Annual SCDM conference. It was a great event and I’m pretty revved up to share what I saw and heard there, especially on the evolving topic of eSource.

One session I’d like to tell you about is an eSource roundtable that was moderated by Linda King, Director of Global Data Delivery at Eli Lilly and Demetris Zambas, VP and Global Head, Data Management at Novartis. Representatives from CDISC, Merck, J&J, AssisTek, Quintiles, and Otsuka rounded out the expert panel.

Response to TransCelerate’s Risk-Based Monitoring Paper: Technology Considerations to Enable Risk-Based Monitoring Methodology

Submitted by Courtney McBean on September 30, 2014 - 1:46pm

Have you had a chance to read the latest TransCelerate paper on risk-based monitoring (RBM)?

If not, I highly recommend getting your eyes on Technology Considerations to Enable the Risk-Based Monitoring Methodology, published online in August on behalf of the Drug Information Association (DIA). This paper serves as a tremendous resource for any organization interested in new enterprise technology to help realize the advantages of risk-based monitoring.

Highlights from the 2014 Osteoarthritis Imaging Workshop

Submitted by Eli Berdougo on September 23, 2014 - 2:58pm
Highlights from the 2014 Osteoarthritis Imaging Workshop

This summer, experts from academia, industry and regulatory sectors gathered in Reykjavik, Iceland for The International Workshop on Osteoarthritis Imaging (IWOAI) to discuss the latest advances related to imaging in Osteoarthritis (OA). Presentations at this conference centered on new imaging techniques and analytical methods for monitoring OA pathophysiology and evaluating imaging data from clinical studies.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BIOC News: Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit 03/20/2018 08:05:00 AM
BIOC News: Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research ... 03/15/2018 08:05:00 AM
BIOC News: Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018 03/12/2018 08:05:00 AM
BIOC News: Biocept to Present at the 30th Annual ROTH Conference 03/06/2018 08:05:00 AM
BIOC News: Current Report Filing (8-k) 02/12/2018 05:21:43 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1406   E-trade shows 5,239,707 shares trades @ +7.98% closing baldfatugly 03/24/18 11:10:16 AM
#1405   Good morning, BIOC sgunderbarth 03/20/18 10:37:05 AM
#1404   Looks the one may be able to get Yo-Yo 03/16/18 11:38:30 AM
#1403   BIOC Testing major resistance. Getting hot in here. sgunderbarth 03/16/18 10:09:47 AM
#1402   He didn’t kill the... it hasn’t even started. OnceUponADime 03/15/18 07:00:56 PM
#1401   Thanks Clay for killing the run. bks6 03/15/18 05:38:39 PM
#1400   All out earlier @ .40 & .36 area THREE-DAY-TRADER 03/15/18 01:01:02 PM
#1399   Lets See .5O Today zino 03/15/18 09:48:38 AM
#1398   CNN BIOC Forecast is golden! OnceUponADime 03/15/18 07:48:07 AM
#1397   * * $BIOC Video Chart 03-14-18 * * ClayTrader 03/14/18 04:54:24 PM
#1396   .6Ozz My Target zino 03/14/18 02:20:48 PM
#1395   $BIOC ~ It broke .36 resistance & next THREE-DAY-TRADER 03/14/18 12:46:15 PM
#1394   Great Bio- Play zino 03/14/18 12:45:54 PM
#1393   Like I said before, when I was buying stock777777 03/14/18 10:41:58 AM
#1392   Read This... in the last 6 months this OnceUponADime 03/14/18 10:25:56 AM
#1391   Loving the gap down in Feb - This OnceUponADime 03/14/18 09:52:05 AM
#1390   Still holding, target .45-.60! BIOC stock777777 03/13/18 10:55:44 PM
#1389   Seems it's taking off. A move back THREE-DAY-TRADER 03/13/18 11:37:39 AM
#1388   Strong trades. Looking to take a position when OnceUponADime 03/12/18 01:18:16 PM
#1387   Chart has an interesting history and setup from OnceUponADime 03/09/18 11:14:30 AM
#1386   How sweet it is .We have lift off bigarow 03/06/18 11:25:01 AM
#1385   BIOC NEWS bigarow 03/06/18 08:40:16 AM
#1384   BIOC Nice accumulation going on bigarow 03/05/18 01:30:00 PM
#1383   Looking Good ! BIOC stock777777 03/05/18 10:59:03 AM
#1381   $BIOC signed an in-network provider agreement with Wellmark, bigarow 03/02/18 10:16:29 AM
#1380   Adding BIOC !!!! stock777777 03/02/18 09:40:08 AM
#1379   Fridays ugh.Markets showing down again.May take the day off. bigarow 03/02/18 08:25:15 AM
#1378   BIOC Tons of videos on trading bigarow 03/02/18 07:59:17 AM
#1377   Thanx for the advice Biga, I want to Chimer57 03/02/18 07:46:17 AM
#1376   Accumulation going on from Jan 2018.imo bigarow 03/01/18 03:59:32 PM
#1375   BIOC a nazdaq stock.The brokers and MMs are bigarow 03/01/18 03:53:49 PM
#1374   BIOC looks strong ! Av UP ! stock777777 03/01/18 03:53:17 PM
#1373   .34 is 4 mms away bigarow 03/01/18 03:32:32 PM
#1372   I'm using the power of visualization to get bigarow 03/01/18 03:15:20 PM
#1371   Waiting for anything over .45 ! BIOC stock777777 03/01/18 03:14:53 PM
#1370   Not me, I'm in for 11,000 @ .365 Chimer57 03/01/18 03:04:26 PM
#1369   When your in the money sell 1/2.That helps. bigarow 03/01/18 03:00:23 PM
#1368   Ha, ok you got me lol, I'm mostly Chimer57 03/01/18 02:56:18 PM
#1367   ATTACK of the KILLER GREEN CANDELS HAS COMENCED!!!L bigarow 03/01/18 02:56:06 PM
#1366   Looking Good ! BIOC stock777777 03/01/18 02:54:42 PM
#1365   57 chevy WAS that you on that 8K bigarow 03/01/18 02:53:28 PM
#1364   Dow down 447 points. BIOC down .0447 bigarow 03/01/18 02:45:58 PM
#1363 bigarow 03/01/18 02:39:51 PM
#1362   Notice the largest buys are higher than bid bigarow 03/01/18 02:35:40 PM
#1361   Nice observation.I know that's not BIOC.Just thought you bigarow 03/01/18 02:29:52 PM
#1360   Watch and learn ! BIOC stock777777 03/01/18 01:52:53 PM
#1359   It looks like you are misinformed, Biotics Research Chimer57 03/01/18 01:39:45 PM
#1358   Dow drops 300 points.BIOC drops .03 bigarow 03/01/18 01:22:08 PM
#1357   Lunch almost over.Price action will pick up bigarow 03/01/18 01:19:21 PM
#1356   ADD.FOR BIOC = bigarow 03/01/18 11:26:06 AM